FDA panel calls for label changes, more education on menopausal hormone therapy
Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and health care professionals.
Related Articles
BELIEVE spotlights quality and quantity approach to weight management with combo therapy – ADA Meeting News
Steven B. Heymsfield, MD, and other panelists discussed how bimagrumab can preserve the weight reduction seen with semaglutide while also improving body composition.
SGLT-2 inhibitor reduces risk for mortality in patients with COPD, type 2 diabetes
Patients with COPD and type 2 diabetes had a reduced risk for COPD hospitalization, noninvasive positive-pressure ventilation and all-cause mortality if they used an SGLT-2…
Women’s Health | ADA
Women’s health is crucial to overall health care. Diabetes—whether gestational, type 1, or type 2—poses unique challenges for women at every life stage, making focused…
CPAP use may drive lower mortality in patients with IPF plus OSA vs. IPF only
SAN FRANCISCO — Fewer patients with idiopathic pulmonary fibrosis and obstructive sleep apnea died vs. patients with idiopathic pulmonary fibrosis alone, according to data presented…
Trump diagnosed with chronic venous insufficiency
The White House announced President Donald J. Trump has been diagnosed with chronic venous insufficiency after observations of lower extremity swelling.During a press conference, press…
Language evolves — so can you
Nature Reviews Endocrinology – As healthcare professionals, scientists and educators, our intent is to empower people affected by diabetes mellitus; however, if our language is…
Tirzepatide Cardiometabolic Benefits Greater in Women vs Men
Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.
Diabetes Medical Management Plan | American Diabetes Association
Ensure standardized and efficient diabetes care in schools with our updated DMMP form. Tailor care instructions for individual students, providing clarity for caregivers.
FDA fast tracks one-time intravitreal gene therapy for geographic atrophy
 The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, according to…
High-cost immunotherapy increases likelihood of financial hardship among cancer survivors
Cancer survivors who received high-cost immunotherapies appear more likely to experience financial hardship, according to study results published in Journal of Cancer Survivorship.Financial hardship, including…
